Are APLS, CNTA, BIRD Obtaining Fair Deals for their Shareholders?

Rhea-AI Summary

{"summary":"","positive":[],"negative":[],"faq":[]}

Key Figures

Allbirds asset sale price: $39 million Apellis sale price: $41.00 per share Apellis CVR payments: $2.00 per share each (two payments) +5 more

8 metrics

Allbirds asset sale price $39 million Sale of intellectual property and certain assets to American Exchange Group

Apellis sale price $41.00 per share Cash consideration in sale to Biogen (APLS transaction)

Apellis CVR payments $2.00 per share each (two payments) Contingent value right tied to SYFOVRE sales thresholds

Centessa sale price $38.00 per share Cash consideration in sale to Eli Lilly (CNTA transaction)

Centessa CVR potential Up to $9.00 per share Non-transferable CVR contingent on milestone achievement

2025 net loss $77.3 million Allbirds full-year 2025 loss reported in 10-K

2025 operating cash use $55.1 million Cash used in operating activities in 2025

ATM stock program size $50 million At-the-market equity program noted in 10-K

Market Reality Check

Price: $3.02 Vol: Volume 28,328 is 0.5x the...

low vol

$3.02 Last Close

Volume Volume 28,328 is 0.5x the 20-day average of 56,268, indicating muted trading relative to recent norms. low

Technical Shares at 3.015 trade below the 200-day MA of 6.12 and sit 76.54% below the 52-week high of 12.85, though still 25.63% above the 52-week low of 2.40.

Peers on Argus

BIRD’s -6.29% move occurred alongside scanner-flagged peers like DBGI at -4.02% ...

2 Down

BIRD’s -6.29% move occurred alongside scanner-flagged peers like DBGI at -4.02% and JILL at -29.15%, with 2 peers moving down and none up. This aligns with broader apparel retail pressure noted as a sector move.

Common Catalyst No peer company news was flagged; downside moves appear driven by broader sector dynamics rather than company-specific headlines alone.

Historical Context

5 past events · Latest: Mar 10 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 10	Earnings call notice	Neutral	-11.3%	Scheduled Q4 and full-year 2025 earnings release and conference call announcement.
Feb 09	Product launch	Positive	-5.1%	Launch of Terralux collection using INNOVERA leather alternative and new materials.
Feb 03	Marketing campaign	Positive	-7.5%	Spring/Summer 2026 “Say Yes” campaign featuring new collections and products.
Jan 28	Restructuring update	Neutral	+1.3%	Decision to close remaining full-price U.S. stores to focus on capital-light channels.
Nov 06	Earnings results	Negative	-21.2%	Q3 2025 results showing revenue decline, sizeable net loss and negative guidance update.

Pattern Detected

Recent history shows frequent negative reactions even to product and marketing news, with only one clearly negative earnings event aligning with a sharp selloff.

Recent Company History

Over the past several months, Allbirds announced retail store closures to support profitable growth, launched new product lines and campaigns, and reported weak Q3 2025 results with revenue declines and continued losses. Those updates often saw the stock trade down, including a -21.16% move on Q3 earnings. The latest article highlights legal scrutiny of the announced $39 million asset sale, which follows an 8-K detailing plans to sell substantially all assets and later dissolve the company.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-06-30

The company has an effective S-3 shelf registration filed on 2025-06-30, with at least one usage via a 424B5 prospectus supplement on 2025-07-18, indicating established capacity to issue securities under this program.

Market Pulse Summary

This announcement highlights a law firm’s investigation into whether Allbirds shareholders are recei...

Analysis

This announcement highlights a law firm’s investigation into whether Allbirds shareholders are receiving fair treatment in the proposed $39 million asset sale to an affiliate of American Exchange Group. It follows prior SEC filings noting continued losses, liquidity pressure, and a plan to sell substantially all assets and then dissolve the company. Investors may focus on deal terms, potential competing offers, board process, and any additional disclosures that emerge from this legal scrutiny.

Key Terms

contingent value right, fiduciary duties, securities laws

3 terms

contingent value right financial

"a nontransferable contingent value right for the right to receive two payments"

A contingent value right is a special security that gives its holder the right to receive one or more future payments only if specified events happen, such as a product reaching a sales target or getting regulatory approval. It matters to investors because it offers potential extra payout tied to uncertain outcomes—like a bet that a project will succeed—so it can add upside to a deal while also carrying extra risk and valuation uncertainty.

fiduciary duties regulatory

"breaches of fiduciary duties to shareholders relating to"

Fiduciary duties are the legal and ethical responsibilities that company directors, officers, or financial advisors have to put shareholders’ interests ahead of their own, acting with honesty, care, and loyalty. Think of it like a guardian managing someone’s money: choices must prioritize the owner’s benefit, avoid conflicts, and be made with prudent judgment; investors rely on these duties to ensure decisions aren’t self‑serving and to provide grounds for legal action if abused.

securities laws regulatory

"potential violations of the federal securities laws and/or breaches"

Securities laws are the rules and enforcement systems that govern the buying, selling and disclosure of stocks, bonds and other investment products; think of them as the traffic laws for financial markets that set what must be disclosed, forbid fraud and require fair dealing. They matter to investors because they help ensure companies provide accurate information, reduce the risk of deception or insider advantage, and make it easier to compare investments and seek remedies if something goes wrong.

AI-generated analysis. Not financial advice.

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

The proposed transactions may contain terms that could limit superior competing offers.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

NEW YORK, March 31, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)'s sale to Biogen Inc. for $41.00 per share in cash and a nontransferable contingent value right for the right to receive two payments of $2.00 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE. If you are an Apellis shareholder, click here to learn more about your legal rights and options.

Centessa Pharmaceuticals plc (NASDAQ: CNTA)'s sale to Eli Lilly and Company for $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones. If you are a Centessa shareholder, click here to learn more about your legal rights and options.

Allbirds, Inc.'s (NASDAQ: BIRD)'s sale of its intellectual property and certain other assets to American Exchange Group for $39 million. If you are an Allbirds shareholder, click here to learn more about your legal rights and options.

On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
One World Trade Center
85th Floor
New York, NY 10007
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/are-apls-cnta-bird-obtaining-fair-deals-for-their-shareholders-302730253.html

SOURCE Halper Sadeh LLP